Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 9
1980 2
1981 4
1982 2
1983 1
1984 4
1986 1
1987 2
1988 8
1989 9
1990 5
1991 2
1992 8
1993 6
1994 8
1995 2
1996 2
1997 4
1998 4
1999 5
2000 8
2001 9
2002 3
2003 20
2004 27
2005 25
2006 28
2007 43
2008 52
2009 49
2010 42
2011 59
2012 73
2013 90
2014 71
2015 86
2016 87
2017 94
2018 111
2019 92
2020 138
2021 165
2022 84
Text availability
Article attribute
Article type
Publication date

Search Results

1,411 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Zhu FC, et al. Among authors: li jx. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.
Drug addiction: a curable mental disorder?
Liu JF, Li JX. Liu JF, et al. Among authors: li jx. Acta Pharmacol Sin. 2018 Dec;39(12):1823-1829. doi: 10.1038/s41401-018-0180-x. Epub 2018 Oct 31. Acta Pharmacol Sin. 2018. PMID: 30382181 Free PMC article. Review.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Zhu FC, et al. Among authors: li jx. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. Lancet. 2020. PMID: 32450106 Free PMC article. Clinical Trial.
Preface.
Li JX. Li JX. Adv Pharmacol. 2022;93:xiii-xiv. doi: 10.1016/S1054-3589(22)00014-X. Adv Pharmacol. 2022. PMID: 35341575 No abstract available.
Defective STING expression potentiates IL-13 signaling in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps.
Wang H, Hu DQ, Xiao Q, Liu YB, Song J, Liang Y, Ruan JW, Wang ZZ, Li JX, Pan L, Wang MC, Zeng M, Shi LL, Xu K, Ning Q, Zhen G, Yu D, Wang DY, Wenzel SE, Liu Z. Wang H, et al. Among authors: li jx. J Allergy Clin Immunol. 2021 May;147(5):1692-1703. doi: 10.1016/j.jaci.2020.12.623. Epub 2020 Dec 17. J Allergy Clin Immunol. 2021. PMID: 33340608
Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling.
Li JX, Li RZ, Sun A, Zhou H, Neher E, Yang JS, Huang JM, Zhang YZ, Jiang ZB, Liang TL, Ma LR, Wang J, Wang XR, Fan XQ, Huang J, Xie Y, Liu L, Tang L, Leung EL, Yan PY. Li JX, et al. Pharmacol Res. 2021 Sep;171:105574. doi: 10.1016/j.phrs.2021.105574. Epub 2021 Jul 25. Pharmacol Res. 2021. PMID: 34419228
1,411 results